Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Equivalents (2016 - 2025)

Iovance Biotherapeutics has reported Cash & Equivalents over the past 12 years, most recently at $163.1 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $163.1 million for Q4 2025, up 40.96% from a year ago — trailing twelve months through Dec 2025 was $163.1 million (up 40.96% YoY), and the annual figure for FY2025 was $163.1 million, up 40.96%.
  • Cash & Equivalents for Q4 2025 was $163.1 million at Iovance Biotherapeutics, up from $158.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IOVA hit a ceiling of $543.5 million in Q1 2023 and a floor of $114.9 million in Q4 2023.
  • Median Cash & Equivalents over the past 3 years was $163.6 million (2024), compared with a mean of $202.0 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 75.31% in 2024 and later surged 40.96% in 2025.
  • Iovance Biotherapeutics' Cash & Equivalents stood at $114.9 million in 2023, then increased by 0.7% to $115.7 million in 2024, then surged by 40.96% to $163.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $163.1 million (Q4 2025), $158.1 million (Q3 2025), and $132.5 million (Q2 2025) per Business Quant data.